HC Wainwright Has Positive Outlook for COGT Q1 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – HC Wainwright boosted their Q1 2026 earnings per share estimates for Cogent Biosciences in a report released on Tuesday, March 17th. HC Wainwright analyst R. Burns now forecasts that the technology company will post earnings per share of ($0.53) for the quarter, up from their previous estimate of ($0.54). HC Wainwright has a “Buy” rating and a $52.00 price objective on the stock. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Cogent Biosciences’ Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($2.21) EPS.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings results on Tuesday, February 17th. The technology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04).

Several other brokerages have also recently issued reports on COGT. JPMorgan Chase & Co. upped their price target on shares of Cogent Biosciences to $67.00 and gave the company an “overweight” rating in a research report on Friday, December 19th. Piper Sandler lifted their price target on shares of Cogent Biosciences from $39.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Jefferies Financial Group began coverage on Cogent Biosciences in a report on Monday. They issued a “buy” rating and a $55.00 price objective for the company. Wall Street Zen lowered Cogent Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Finally, Robert W. Baird set a $35.00 target price on Cogent Biosciences in a report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $43.45.

Cogent Biosciences Stock Up 0.7%

NASDAQ:COGT opened at $34.61 on Thursday. Cogent Biosciences has a one year low of $3.72 and a one year high of $43.73. The company has a debt-to-equity ratio of 0.41, a current ratio of 14.23 and a quick ratio of 14.23. The company has a market cap of $5.62 billion, a PE ratio of -16.02 and a beta of 0.47. The firm’s 50 day simple moving average is $37.30 and its 200 day simple moving average is $29.44.

Insider Activity

In other news, insider Evan Kearns sold 65,000 shares of the company’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $38.70, for a total value of $2,515,500.00. Following the sale, the insider directly owned 109,398 shares of the company’s stock, valued at approximately $4,233,702.60. This represents a 37.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Fairmount Funds Management Llc sold 3,500,000 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $36.40, for a total transaction of $127,400,000.00. Following the sale, the director owned 5,503,418 shares of the company’s stock, valued at approximately $200,324,415.20. This trade represents a 38.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,737,642 shares of company stock worth $136,600,345 over the last quarter. Company insiders own 7.29% of the company’s stock.

Institutional Trading of Cogent Biosciences

Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC raised its position in shares of Cogent Biosciences by 482.6% in the 1st quarter. AQR Capital Management LLC now owns 160,767 shares of the technology company’s stock worth $963,000 after acquiring an additional 133,174 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Cogent Biosciences by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,275 shares of the technology company’s stock valued at $377,000 after purchasing an additional 3,693 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Cogent Biosciences by 14.3% during the first quarter. Goldman Sachs Group Inc. now owns 988,962 shares of the technology company’s stock worth $5,924,000 after purchasing an additional 124,069 shares during the period. Jane Street Group LLC grew its stake in Cogent Biosciences by 66.2% during the first quarter. Jane Street Group LLC now owns 123,822 shares of the technology company’s stock worth $742,000 after purchasing an additional 49,338 shares during the period. Finally, Strs Ohio bought a new stake in Cogent Biosciences in the first quarter worth approximately $36,000.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.